Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Prostate stem cell antigen (PSCA) is member of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI) anchored surface proteins, which localized to the cell surface, anchored by a GPI linkage. PSCA is expressed in the basal and secretory epithelial cell layers as well as neuroendocrine cells of human prostate. Besides, it expression is found in the placenta, bladder, neuroendocrine cells of the stomach and colon, and weekly in the kidneys excluding the glomeruli as well. In addition to the identification of PSCA as a prostate tumor associated protein, several other tumors have shown associations with PSCA such as pancreatic adenocarcinoma, transitional cell carcinoma, renal cell carcinoma and diffuse-type gastric cancer.
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-T-1-L347-2 | Anti-PSCA scFv h(CD28) CART, pCDCAR1 | Human | scFv-CD28 | Lentiviral | T cell | ||||
| CAR-T-1-L347-G | Anti-PSCA scFv h(FcεRIγ) CART, pCDCAR1 | Human | scFv-FcεRIγ | Lentiviral | T cell | ||||
| CAR-T-1-L347-Z | Anti-PSCA scFv h(CD3ζ) CART, pCDCAR1 | Human | scFv-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-2-L347-2G | Anti-PSCA scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | scFv-CD28-FcεRIγ | Lentiviral | T cell | ||||
| CAR-T-2-L347-2Z | Anti-PSCA scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-2-L347-4G | Anti-PSCA scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | scFv-CD4-FcεRIγ | Lentiviral | T cell | ||||
| CAR-T-2-L347-4Z | Anti-PSCA scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | scFv-CD4-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-2-L347-8Z | Anti-PSCA scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | scFv-CD8-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-2-L347-BZ | Anti-PSCA scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-2-L347-CZ | Anti-PSCA scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | scFv-b2c-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-3-L347-2BZ | Anti-PSCA scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | ||||
| CAR-T-3-L347-2XZ | Anti-PSCA scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | ||||
| CAR-LC275 | Anti-PSCA (1G8) h(CD28-CD3ζ, MyD88) Conditional CAR, pCDCAR1 | Human | 1G8 | Human | Retroviral | T cell | |||
| CAR-MZ037 | Anti-PSCA (bm2B3) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | bm2B3 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-MZ038 | Anti-PSCA (Ha1-4.117 ) h(CD3ζ) CAR, pCDCAR1 | Human | Ha1-4.117 | Human | scFv-CD3ζ | Lentiviral | T cell | ||
| CAR-MZ039 | Anti-PSCA (Ha1-4.117 ) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Ha1-4.117 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
| CAR-MZ091 | Anti-PSCA (AM1) h(DAP12) CAR, pCDCAR1 | Human | AM1 | Human | scFv-DAP12 | Lentiviral | NK cell | ||
| CAR-MZ092 | Anti-PSCA (AM1) h(CD3ζ) CAR, pCDCAR1 | Human | AM1 | Human | scFv-CD3ζ | Lentiviral | NK cell | ||
| CAR-MZ156 | Anti-PSCA (7F5) h(CD3ζ) CAR, pCDCAR1 | Human | 7F5 | Mouse | scFv-CD3ζ | Lentiviral | T cell | ||
| CAR-MZ157 | Anti-PSCA (7F5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7F5 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
